Information Provided By: 
Fly News Breaks for March 5, 2020
BMY
Mar 5, 2020 | 06:27 EDT
BofA analyst Geoff Meacham keeps his Buy rating and $75 price target on Bristol-Myers but adds it to his U.S. 1 List given the "moderate pressure" on the stock in recent weeks. The analyst believes that the valuation on the shares is "particularly attractive" at its current 9.5-times earnings multiple vs. the peer group average of 14.5-times, adding that his top pick in biopharma thesis for the company in 2020 has not changed. Meacham believes Bristorl-Myers is oversold in the midst of the coronavirus concerns.
News For BMY From the Last 2 Days
